At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
ACTH geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center, Randomized, Phase II Study of the Safety,Efficacy and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis
In Brief
A Phase 2 clinical trial evaluating ACTH gel for Uveitis. Completed, enrolled 28 participants across 7 sites.
Detailed Summary
The study aims to evaluate the potential role of ACTH gel in the management of non-infectious uveitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
CountriesUnited States
CollaboratorsMallinckrodt
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2017
Primary CompletionApr 2020
Study CompletionOct 2021
TodayJul 2026
First PostedOct 12, 2016
Enrollment StartNov 10, 2017
Primary CompletionApr 3, 2020
Study CompletionOct 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.7 years ago
Interventions
ACTH geldrug
Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.